About DiagMetrics
Founded in 2020, DiagMetrics is advancing mask-based solutions for rapid diagnosis of COVID-19 with the aim to democratize testing. We’re developing tests for multiple other conditions using exhaled breath condensate such as Tuberculosis, Flu A/Flu B, and RSV.
Mission: Improving Healthcare Accessibility
Democratizing diagnostics with priority to accessibility, user-friendliness, and effectiveness.
We believe in empowering individuals and healthcare professionals through remote patient monitoring with actionable insights, ultimately improving health outcomes worldwide.
Values & Vision
- Continuous improvement
- Ownership and accountability
- Community, especially the disadvantaged
- Rapid product development without sacrifice in quality
DiagMetrics Leadership Team
Our co-founders bring over 75 years of combined experience in high growth, entrepreneurial settings including medical, intellectual property, software, technology, alternative energy, energy efficiency, and traditional energy.
John J. Daniels, BS, JD: CEO
Inventor and co-founder
A proven innovator with notable inventions sold to industry leading companies. John holds over 40 patents. He has 25 years of career experience as an engineer and inventor, is a registered U.S. patent attorney, and a can take an invention from concept to prototype and commercialization.
Ken DeCubellis, MS, MBA
Co-founder
Ken has served as CEO of public and private energy companies and was and CEO of a NASDAQ (SPAC) that raised $140 million in an IPO and completed a transaction creating NASDAQ: AESE. He has raised over $250 million of private and public equity, debt and strategic investments.
Shekhar Wadekar, PhD, MBA
Co-founder
Shekhar has several years of experience in investment banking/equity research, managing and financing technology companies. He was co-founder of a NASDAQ SPAC that raised $57 million. He was Technical Coordinator of the IBM-Siemens-Toshiba Joint Venture to develop semiconductor technology.
DiagMetrics News
Visit the news center for the most recent product updates, publications, and announcements.
DiagMetrics Secures Key U.S. Patents Covering Breath-Based Diagnostics and Strengthens Intellectual Property Leadership
DiagMetrics, Inc. has been granted three U.S. patents — 12,369,816; 12,092,639; and 12,031,982 — covering its Mask-Based Diagnostic™ (MBD™) platform for collecting and analyzing exhaled breath condensate (EBC). These patents secure broad protection for the company’s innovations in EBC collection, diagnostic integration with rapid assays and biosensors, and thermal mass condensation technologies. The new IP strengthens DiagMetrics’ leadership in non-invasive, breath-based diagnostics, supporting its mission to deliver affordable, scalable solutions for global health challenges including infectious disease, oncology, cardiology, and chronic disease monitoring
DiagMetrics Developing Capture Molecule- and Biosensor-Based Breath Assays
Startup DiagMetrics plans to parlay novel sample collection and detection technologies into home-use and point of care tests, and was recently awarded funding.
DiagMetrics Recieves NIH RADx® Funding
DiagMetrics has recieved an NIH RADx® award to advance its mask-based diagnostic platform.